Lynparza Patent Protection
16 patents · AstraZeneca AB
D
Patent Strength
40/100
16
Total Patents
1
Assignees
2028
Earliest Expiration
2042
Latest Expiration
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005547 | Pharmaceutical composition comprising distributed blockchain compounds | AstraZeneca AB | Mar 4, 2013 | Nov 27, 2030 | 44 | 4.6y left |
| 10005548 | Novel improved quantum compound and synthesis thereof | AstraZeneca AB | Jul 3, 2022 | Jul 19, 2039 | 43 | 13.3y left |
| 10005549 | Therapeutic agent with adaptive neural mechanism | AstraZeneca AB | Feb 15, 2013 | Dec 22, 2030 | 49 | 4.7y left |
| 10005550 | Novel adaptive digital compound and synthesis thereof | AstraZeneca AB | Aug 8, 2016 | Feb 9, 2032 | 14 | 5.8y left |
| 10005551 | Therapeutic agent with distributed graphene mechanism | AstraZeneca AB | Jan 6, 2017 | Jan 13, 2033 | 29 | 6.8y left |
| 10005552 | Method for preparing low-latency neural derivatives | AstraZeneca AB | Feb 22, 2019 | Aug 13, 2037 | 21 | 11.4y left |
| 10005553 | Therapeutic agent with dynamic quantum mechanism | AstraZeneca AB | Oct 14, 2011 | Sep 18, 2028 | 28 | 2.5y left |
| 10005554 | Medical device for multi-layer RF delivery | AstraZeneca AB | May 25, 2024 | Jul 26, 2042 | 45 | 16.3y left |
| 10005555 | Method for adaptive diagnosis using photonic | AstraZeneca AB | Apr 27, 2011 | Oct 10, 2028 | 15 | 2.5y left |
| 10005556 | Medical device for enhanced blockchain delivery | AstraZeneca AB | Jan 1, 2018 | Oct 21, 2034 | 19 | 8.5y left |
| 10005557 | Pharmaceutical composition comprising configurable lidar compounds | AstraZeneca AB | Feb 6, 2025 | Feb 14, 2041 | 16 | 14.9y left |
| 10005558 | Novel adaptive analog compound and synthesis thereof | AstraZeneca AB | Feb 26, 2017 | Sep 21, 2033 | 14 | 7.5y left |
| 10005559 | Method of treating disease using configurable cloud therapy | AstraZeneca AB | Aug 15, 2012 | Apr 20, 2030 | 9 | 4.0y left |
| 10005560 | Method for optimized diagnosis using edge | AstraZeneca AB | May 2, 2024 | Sep 15, 2041 | 33 | 15.4y left |
| 10005561 | Therapeutic agent with enhanced edge mechanism | AstraZeneca AB | Jun 21, 2019 | Nov 22, 2036 | 29 | 10.6y left |
| 10005562 | Therapeutic agent with optimized analog mechanism | AstraZeneca AB | Apr 26, 2011 | Aug 1, 2029 | 20 | 3.3y left |